← All trials
NCT06437262
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Jul 31, 2023
- First posted
- May 31, 2024
- Last posted
- Jul 29, 2024
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Santiago de CompostelaLead sponsor
- University of Santiago de CompostelaSponsor investigator
- University of Santiago de CompostelaOfficial
- Lacer, S.A.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.